Sevim GÖNEN, Ajlan TÜKÜN, Hasan YETER, Özant HELVACI, Berfu KORUCU, Galip GÜZ, Turgay ARINSOY

Vitamin D receptor polymorphisms and bone health after kidney transplantation

Background/aim: Bone disease is one of the most prominent complications after kidney transplantation. Bone diseases include osteoporosis, persistent secondary hyperparathyroidism, and avascular necrosis (AVN). We investigated the relationship between the polymorphisms of the vitamin D receptor (VDR) gene and bone diseases occurring after kidney transplantation. Materials and methods: The study consists of 234 kidney allograft recipients with a minimum follow-up of five years after kidney transplantation. Patients with glomerular filtration rates less than 30 mL/min/1.73m2, a history of parathyroidectomy, bisphosphonate use pre- or post-transplantation, and cinacalcet use posttransplantation excluded. We evaluated associations between the polymorphisms of the VDR gene (BsmI, TaqI, ApaI, FokI, and Cdx2), the first-year bone mineral density (BMD) scores, persistent secondary hyperparathyroidism, and AVN. Results: Patients with low BMD scores were significantly younger (P = 0.03) and had higher intact parathormone (iPTH) levels (P = 0.03). Cdx2 TT genotype significantly increases the risk of low BMD scores (OR: 3.34, P = 0.04). Higher phosphate levels were protective against abnormal BMD scores (OR: 0.53; P = 0.03). Patients with persistent hyperparathyroidism had significantly longer dialysis vintage and higher pretransplantation iPTH levels (P = 0.02 and P < 0.001, respectively). Cdx2, CT/TT, and ApaI CA/AA genotypes significantly increase the risk of persistent hyperparathyroidism (OR: 6.81, P < 0.001, OR: 23.32, P < 0.001, OR:4.01, P = 0.02, and OR: 6.30, P = 0.01; respectively). BsmI CT/TT genotypes were found to increase AVN risk with an HR of 3.48 (P = 0.03). Higher hemoglobin levels were also found to decrease AVN risk with an HR of 0.76 (P = 0.05). Conclusion: Certain VDR gene polymorphisms are associated with a higher risk for bone diseases after kidney transplantation.Key words: Kidney transplantation, VDR polymorphisms, osteoporosis, avascular necrosis, persistent hyperparathyroidism

PDF

___

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. New England Journal of Medicine 1999; 341 (23): 1725-1730. doi: 10.1056/NEJM199912023412303
2. Hruska KA, Teitelbaum SL. Renal osteodystrophy. New England Journal of Medicine 1995; 333 (3): 166-175. doi: 10.1056/ NEJM199507203330307
3. Dounousi E, Leivaditis K, Eleftheriadis T, Liakopoulos V. Osteoporosis after renal transplantation. International Urology and Nephrology 2015; 47 (3): 503-511. doi: 10.1007/s11255- 014-0862-3
4. Park W, Han S, Choi B, Park C, Yang C et al. Progression of osteoporosis after kidney transplantation in patients with endstage renal disease. Transplantation Proceedings2017; 49 (5): 1033-1037. doi: 10.1016/j.transproceed.2017.03.038
5. Cunningham J. Posttransplantation bone disease. Transplantation 2005; 79 (6): 629-634. doi: 10.1097/01. tp.0000149698.79739.ef
6. Ozel L, Ata P, Ozel M, Toros A, Kara M et al. Risk factors for osteoporosis after renal transplantation and effect of vitamin D receptor Bsm I polymorphism. Transplantation Proceedings 2011; 43 (3): 858-862. doi: 10.1016/j.transproceed.2011.02.075
7. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrology Dialysis Transplantation 2004; 19 (5): 1281-1287. doi: 10.1093/ndt/gfh128
8. Nagaba Y, Heishi M, Tazawa H, Tsukamoto Y, Kobayashi Y. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. American Journal of Kidney Diseases 1998; 32 (3): 464-469. doi: 10.1053/ajkd.1998. v32.pm9740163
9. Yamamoto Y, Yoshizawa T, Fukuda T, Shirode-Fukuda Y, Yu T et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology 2013; 154 (3): 1008-1020. doi: 10.1210/en.2012-1542
10. Pouya F, Kerachian MA. Avascular necrosis of the femoral head: are any genes involved? Archives of Bone and Joint Surgery 2015; 3 (3): 149. doi: 10.22038/ABJS.2015.4294
11. World Health Organization (WHO). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. Geneva, Switzerland: WHO; 1994.
12. Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM et al. Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. Journal of Clinical Densitometry 2016; 19 (2): 127-140. doi: 10.1016/j.jocd.2016.03.003
13. Pihlstrøm H, Dahle DO, Mjøen G, Pilz S, März W et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation 2015; 99 (2): 351-359. doi: 10.1097/ TP.0000000000000583
14. Miyamoto K-i, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Molecular Endocrinology 1997; 11 (8): 1165-1179. doi: 10.1210/ mend.11.8.9951
15. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338 (2): 143-156. doi: 10.1016/j.gene.2004.05.014
16. Van Staa T, Leufkens H, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis International 2002; 13 (10): 777-787. doi: 10.1007/ s001980200108
17. Movsowitz C, Epstein S, Fallon Mea, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123 (5): 2571-2577. doi: 10.1210/endo-123-5-2571
18. Cayco Av, Wysolmerski J, Simpson C, Mitnick MA, Gundberg C et al. Posttransplant bone disease: evidence for a high bone resorption state. Transplantation 2000; 70 (12): 1722-1728. doi: 0041-1337/00/7012-1722/0
19. Cueto-Manzano AM, Konel S, Crowley V, France MW, Freemont AJ et al. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 2003; 75 (12): 2053-2058. doi: 10.1097/01.tp.0000068869.21770.f6
20. Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D et al. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level metaanalysis. Annals of Internal Medicine 2006; 145 (4): 255-264. doi: 10.7326/0003-4819-145-4-200608150-00005
21. Shen H, Xie J, Lu H. Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis. Climacteric 2014; 17 (4): 319-324. doi: 10.3109/13697137.2013.856401
22. Marco M, Martinez I, Betriu A, Craver L, Fibla M et al. Influence of Bsml vitamin D receptor gene polymorphism on the response to a single bolus of calcitrol in hemodialysis patients. Clinical Nephrology 2001; 56 (2): 111-116. doi: 10.1186/ s12882-018-0831-7
23. Yokoyama K, Shigematsu T, Tsukada T, Ogura Y, Takemoto F et al. Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney International 1998; 53 (2): 454-458. doi: 10.1046/j.1523-1755.1998.0078.x
24. Chudek J, Karkoszka H, Schmidt-Gayk H, Ritz E, Kokot F. Plasma parathyroid hormone, phosphatemia and vitamin D receptor genotype: are they interrelated? Journal of Nephrology 2000;13 (1): 54-58. doi: 10.1093/ndt/gfq019
25. Waziri B, Dix-Peek T, Dickens C, Duarte R, Naicker S. Influence of vitamin D receptor polymorphisms on biochemical markers of mineral bone disorders in South African patients with chronic kidney disease. BMC Nephrology 2018; 19 (1): 30. doi: 10.1186/s12882-018-0831-7
26. Gago EV, Cadarso-Suarez C, Perez-Fernandez R, Burgos RR, Mugica JD et al. Association between vitamin D receptor Fokl polymorphism and serum parathyroid hormone level in patients with chronic renal failure. Journal of Endocrinological Investigation 2005; 28 (4): 117-121. doi: 10.1007/BF03345353
27. Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus: relationship to corticosteroid therapy. Archives of Internal Medicine 1978; 138 (5): 750-754. doi: 10.1001/archinte.1978.03630290052018
28. Dilisio MF. Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients. Orthopedics 2014; 37 (7): e631-e636. doi: 10.3928/01477447- 20140626-54
29. Zizic TM, Marcoux C, Hungerford D, Dansereau J-V, Stevens M. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. The American Journal of Medicine 1985; 79 (5): 596-604. doi: 10.1016/0002- 9343(85)90057-9
30. Hadjigeorgiou G, Dardiotis E, Dardioti M, Karantanas A, Dimitroulias A et al. Genetic association studies in osteonecrosis of the femoral head: mini review of the literature. Skeletal Radiology 2008; 37 (1): 1-7. doi: 10.1007/s00256-007-0395-2
31. ElHarouni D, Yassin D, Ali N, Gohar S, Zaky I et al. A pharmacogenetic study of VDR fok1 and TYMS polymorphisms and their association with glucocorticoid-induced osteonecrosis in Egyptian children with acute lymphoblastic leukemia. Frontiers in Oncology 2018; 8: 1-7. doi: 10.3389/fonc.2018.00541
32. Adekile A, Gupta R, Yacoub F, Sinan T, Al-Bloushi M et al. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of α-thalassemia trait. Acta Haematologica 2001; 105 (1): 27-31. doi: 10.1159/000046529
33. Narayanan A, Khanchandani P, Borkar RM, Ambati CR, Roy A et al. Avascular necrosis of femoral head: a metabolomic, biophysical, biochemical, electron microscopic and histopathological characterization. Scientific Reports 2017; 7 (1): 10721. doi: 10.1038/s41598-017-10817-w
34. Yalçınkaya F, Özçakar ZBrn, Kasapçopur Ö, Öztürk A, Akar N et al. Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. The Journal of Pediatrics 2007; 151 (6): 675-678. doi: 10.1016/j.jpeds.2007.04.062